查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1405831

高血壓藥物市場規模、佔有率和趨勢分析報告：按藥物類別、類型、給藥途徑、配銷通路、地區和細分市場預測，2024-2030年

Anti-hypertensive Drugs Market Size, Share & Trends Analysis Report By Drug Class (Diuretics, ACE Inhibitors), By Type (Primary, Secondary), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10個工作天內

價格

高血壓藥物市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，全球高血壓藥物市場規模將達到306.9億美元，2024年至2030年複合年成長率為3.91%。

高血壓患者數量的增加是推動市場成長的主要因素。此外，肥胖、癌症和心臟病等慢性疾病的增加，以及藥物研發和個人化醫療，正在推動高血壓藥物市場的成長。

正在研發的強大產品顯示出良好的效果是推動抗高血壓藥物市場需求的主要因素。例如，2023 年 9 月，Alnylam Pharmaceuticals, Inc. 宣布其高血壓藥物 dilevesiran 的 2 期試驗達到了主要終點，證明收縮壓顯著降低（24 小時平均值）。 Direvesiran 是一種針對血管緊張素原的 RNAi 療法，給藥，預計將針對需求未滿足的人。

由於高血壓是糖尿病的常見併發症，糖尿病盛行率的增加推動了高血壓藥物市場的成長。高血壓是糖尿病的常見併發症，隨著時間的推移，會損害心臟、血管、腎臟和其他器官。隨著糖尿病盛行率的增加，抗高血壓藥物的需求也預計會增加。根據 IDF 糖尿病地圖集 2021 年第 10 版，20 至 79 歲的成年人患有糖尿病的人數估計為 5.37 億，預計到 2030 年將達到 6.43 億。

政府對研發活動和分銷的資助透過使高血壓藥物更便宜、改善可及性和增加競爭，在促進市場成長方面發揮了作用。例如，2023 年 8 月，Eazymed Technologies Pvt Ltd. 從印度泰米爾納德邦新興部門種子基金籌集了 50 萬美元。該公司計劃將這筆資金用於其供應鏈中的新業務，包括直接與製藥公司合作以及擴大在二、三線城市的業務。這些舉措正在推動高血壓藥物市場的成長。

此外，新型高血壓藥物的核准增加預計將鼓勵製藥公司投資於新型有效治療方法的研發，為主要參與者提供利潤豐厚的機會。例如，2022年5月，FDA核准了Tyvaso DPI（曲前列環素）吸入粉劑。 Tyvaso DPI 是一種乾粉吸入器，可將血管擴張劑曲前列環素直接輸送至肺部。曲前列環素的作用是擴張肺動脈、降低肺部血壓、提升運動能力。

高血壓藥物市場報告亮點

  • 按藥物類別分類，鈣拮抗由於其與其他抗高血壓藥物結合的固有特性，將在 2023 年佔據市場主導地位。
  • 按類型分類，由於用餐、缺乏運動、肥胖、吸煙和過量飲酒等生活方式的改變以及老年人口的增加，原發性高血壓藥物在2023年佔據了最大的市場佔有率。
  • 從給藥途徑來看，口服藥物因其方便、有效和以患者為中心的方法佔據了最大的市場佔有率。
  • 從配銷通路來看，由於全球提供廣泛醫療服務的醫院數量不斷增加，醫院藥房佔據了市場主導地位。
  • 由於私人公司投資增加、有利的政府和保險政策、技術進步以及主要區域營運商，北美已建立了強大的區域地位，市場佔有率為37.55%。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章市場變數、趨勢和範圍

  • 市場區隔和範圍
  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
  • 市場促進因素
    • 高血壓和高血壓盛行率增加
    • 老年人口增加
    • 開發新的、更有效的抗高血壓藥物
  • 市場抑制因素分析
    • 高血壓藥物的副作用
    • 監管挑戰
  • 營商環境分析
    • SWOT 分析；按因素（政治/法律、經濟/技術）
    • 波特五力分析

第4章 藥品類別業務分析

  • 高血壓藥物市場：藥物類別波動分析
  • 利尿劑
  • ACE抑制劑
  • 鈣離子通道阻斷劑
  • BETA-腎上腺素阻斷劑
  • 血管擴張劑
  • 其他

第5章業務分析的類型

  • 高血壓藥物市場：類型變異分析
  • 原發性高血壓
  • 次發性高血壓

第6章給藥途徑業務分析

  • 高血壓藥物市場：給藥途徑變化分析
  • 口服
  • 注射
  • 其他

第7章配銷通路業務分析

  • 高血壓藥物市場：配銷通路波動分析
  • 零售藥房
  • 醫院藥房
  • 網路藥房

第8章區域業務分析

  • 2023年及2030年按地區分類的高血壓藥物市場佔有率
  • 北美洲
    • 2018年至2030年北美高血壓藥物市場估計與預測
    • 美國
    • 加拿大
  • 歐洲
    • 2018年至2030年歐洲高血壓藥物市場估計與預測
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 2018-2030 年亞太地區高血壓藥物市場估計與預測
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 2018年至2030年拉丁美洲高血壓藥物市場估計與預測
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 2018-2030 年 MEA 高血壓藥物市場估計與預測
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章競爭形勢

  • 參與企業概況
  • 財務績效
  • 參與企業
    • 市場領導者
    • 2023年高血壓藥物市場佔有率分析
    • 公司簡介
    • 策略規劃
Product Code: GVR-4-68040-166-1

Anti-hypertensive Drugs Market Growth & Trends:

The global anti-hypertensive drugs market size is expected to reach USD 30.69 billion by 2030, expandingat a CAGR of 3.91% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rising patient base of high blood pressure is the primary factor propelling market growth. Moreover, increasing cases of chronic diseases such as obesity, cancer, and heart disease and innovations in drug discovery & personalized medicine are increasing the growth of anti-hypertensive drugs market.

Presence of strong product in the pipeline demonstrating positive results is a major factor driving the demand for anti-hypertensive drugs market. For instance, in September 2023, Alnylam Pharmaceuticals, Inc. announced the phase 2 study on an investigation drug for the treatment of hypertension, zilebesiran, met the primary end-point and demonstrated significant reduction in the systolic BP (24 hour mean). Zilebesiran is an RNAi therapeutic targeting angiotensinogen which is administered subcutaneously and is expected to target high unmet need in populations.

The growing prevalence of diabetes is fueling the anti-hypertensive drugs market growth, as hypertension is a common complication of diabetes. Over time, hypertension can damage the heart, blood vessels, kidneys, and other organs. As the prevalence of diabetes is growing, the demand for anti-hypertensive drugs is expected to increase. According to the IDF Diabetes Atlas 10th edition 2021, an estimated 537 million adults between the ages of 20-79 years are living with diabetes, and it is expected to reach 643 million by 2030.

Government funding for R&D activities and distribution is playing a role in boosting the market growth by making anti-hypertensive drugs more affordable, improving access, and increasing competition. For instance, in August 2023 , Eazymed Technologies Pvt Ltd. raised USD 500,000 from the Tamil Nadu Emerging Sector Seed Fund in India. The company will utilize the fund on new ventures in the supply chain, such as working directly with pharmaceutical companies to expand their presence in tier 2-3 cities. Such initiatives are boosting the anti-hypertensive drugs market growth.

Moreover, rising approvals of new anti-hypertensive drugs encourage pharmaceutical companies to invest in research & development of novel and effective treatment options, which is expected to offer lucrative opportunities for the key players. For instance, in May 2022, the FDA approved Tyvaso DPI (treprostinil) inhalation powder. Tyvaso DPI is a dry powder inhaler that delivers treprostinil, a vasodilator, directly to the lungs. Treprostinil works by dilating the pulmonary arteries, which reduces blood pressure in the lungs and improves exercise capacity.

Anti-hypertensive Drugs Market Report Highlights:

  • Based on drug class, the calcium channel blockers segment dominated the market in 2023 owing to their intrinsic property in combination with other anti-hypertensive drugs
  • Based on type, the primary hypertension segment held the largest segment share of the market in 2023, owing to the increasing geriatric population and changing lifestyle factors, such as diet, physical inactivity, obesity, smoking, and excessive alcohol consumption
  • Based on route of administration, the oral segment held the largest share due to its convenience, effectiveness, and patient-centered approach
  • Based on distribution channel, the hospital pharmacies dominated the market, owing to the rise in hospitals worldwide, offering a wide range of healthcare services
  • North America has established a strong regional position with a 37.55% market share owing to the increasing investment by private players, favorable government and insurance policies, technological advancements, and key regional operating players

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation
    • 1.1.1. Market Definitions
  • 1.2. Objectives
    • 1.2.1. Objective - 1
    • 1.2.2. Objective - 2
    • 1.2.3. Objective - 3
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. Gvr's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. List Of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Type and Drug Class Snapshot
  • 2.3. Route of Administration and Distribution Channel Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers
    • 3.4.1. Increasing the Prevalence of Hypertension and High Blood Pressure
    • 3.4.2. Growing Geriatric Population
    • 3.4.3. Development of New and More Effective Anti-Hypertensive Drugs
  • 3.5. Market Restraint Analysis
    • 3.5.1. Side Effects of Anti-Hypertensive Drugs
    • 3.5.2. Regulatory Challenges
  • 3.6. Business Environment Analysis
    • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.6.2. Porter's Five Forces Analysis

Chapter 4. Drug Class Business Analysis

  • 4.1. Anti-hypertensive Drugs Market: Drug Class Movement Analysis
  • 4.2. Diuretics
    • 4.2.1. Diuretics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.3. ACE Inhibitors
    • 4.3.1. ACE Inhibitors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Calcium Channel Blockers
    • 4.4.1. Calcium Channel Blockers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Beta-adrenergic Blockers
    • 4.5.1. Beta-adrenergic Blockers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Vasodilators
    • 4.6.1. Vasodilators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Type Business Analysis

  • 5.1. Anti-hypertensive Drugs Market: Type Movement Analysis
  • 5.2. Primary Hypertension
    • 5.2.1. Primary Hypertension Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3. Secondary Hypertension
    • 5.3.1. Secondary Hypertension Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Route of Administration Business Analysis

  • 6.1. Anti-hypertensive Drugs Market: Route of Administration Movement Analysis
  • 6.2. Oral
    • 6.2.1. Oral Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3. Injectables
    • 6.3.1. Injectables Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Others
    • 6.4.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Distribution Channel Business Analysis

  • 7.1. Anti-hypertensive Drugs Market: Route of Administration Movement Analysis
  • 7.2. Retail Pharmacy
    • 7.2.1. Retail Pharmacy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Hospital Pharmacy
    • 7.3.1. Hospital Pharmacy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Online Pharmacy
    • 7.4.1. Online Pharmacy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Regional Business Analysis

  • 8.1. Anti-hypertensive Drugs Market Share By Region, 2023 & 2030
  • 8.2. North America
    • 8.2.1. North America Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. Key Country Dynamics
      • 8.2.2.2. Target Disease Prevalence
      • 8.2.2.3. Competitive Scenario
      • 8.2.2.4. Regulatory Framework
      • 8.2.2.5. Reimbursement Scenario
      • 8.2.2.6. U.S. Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.3. Canada
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Target Disease Prevalence
      • 8.2.3.3. Competitive Scenario
      • 8.2.3.4. Regulatory Framework
      • 8.2.3.5. Reimbursement Scenario
      • 8.2.3.6. Canada Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.2. Germany
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. Target Disease Prevalence
      • 8.3.2.3. Competitive Scenario
      • 8.3.2.4. Regulatory Framework
      • 8.3.2.5. Reimbursement Scenario
      • 8.3.2.6. Germany Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.3. UK
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Target Disease Prevalence
      • 8.3.3.3. Competitive Scenario
      • 8.3.3.4. Regulatory Framework
      • 8.3.3.5. Reimbursement Scenario
      • 8.3.3.6. UK Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Target Disease Prevalence
      • 8.3.4.3. Competitive Scenario
      • 8.3.4.4. Regulatory Framework
      • 8.3.4.5. Reimbursement Scenario
      • 8.3.4.6. France Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.5. Italy
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Target Disease Prevalence
      • 8.3.5.3. Competitive Scenario
      • 8.3.5.4. Regulatory Framework
      • 8.3.5.5. Reimbursement Scenario
      • 8.3.5.6. Italy Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.6. Spain
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Target Disease Prevalence
      • 8.3.6.3. Competitive Scenario
      • 8.3.6.4. Regulatory Framework
      • 8.3.6.5. Reimbursement Scenario
      • 8.3.6.6. Spain Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.7. Denmark
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Target Disease Prevalence
      • 8.3.7.3. Competitive Scenario
      • 8.3.7.4. Regulatory Framework
      • 8.3.7.5. Reimbursement Scenario
      • 8.3.7.6. Denmark Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.8. Sweden
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Target Disease Prevalence
      • 8.3.8.3. Competitive Scenario
      • 8.3.8.4. Regulatory Framework
      • 8.3.8.5. Reimbursement Scenario
      • 8.3.8.6. Sweden Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.9. Norway
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Target Disease Prevalence
      • 8.3.9.3. Competitive Scenario
      • 8.3.9.4. Regulatory Framework
      • 8.3.9.5. Reimbursement Scenario
      • 8.3.9.6. Norway Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Competitive Scenario
      • 8.4.2.4. Regulatory Framework
      • 8.4.2.5. Reimbursement Scenario
      • 8.4.2.6. Japan Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. China
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Competitive Scenario
      • 8.4.3.4. Regulatory Framework
      • 8.4.3.5. Reimbursement Scenario
      • 8.4.3.6. China Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Competitive Scenario
      • 8.4.4.4. Regulatory Framework
      • 8.4.4.5. Reimbursement Scenario
      • 8.4.4.6. India Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.5. South Korea
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Target Disease Prevalence
      • 8.4.5.3. Competitive Scenario
      • 8.4.5.4. Regulatory Framework
      • 8.4.5.5. Reimbursement Scenario
      • 8.4.5.6. South Korea Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.6. Australia
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Target Disease Prevalence
      • 8.4.6.3. Competitive Scenario
      • 8.4.6.4. Regulatory Framework
      • 8.4.6.5. Reimbursement Scenario
      • 8.4.6.6. Australia Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.7. Thailand
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Target Disease Prevalence
      • 8.4.7.3. Competitive Scenario
      • 8.4.7.4. Regulatory Framework
      • 8.4.7.5. Reimbursement Scenario
      • 8.4.7.6. Thailand Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Competitive Scenario
      • 8.5.2.4. Regulatory Framework
      • 8.5.2.5. Reimbursement Scenario
      • 8.5.2.6. Brazil Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Mexico
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Competitive Scenario
      • 8.5.3.4. Regulatory Framework
      • 8.5.3.5. Reimbursement Scenario
      • 8.5.3.6. Mexico Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.4. Argentina
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Competitive Scenario
      • 8.5.4.4. Regulatory Framework
      • 8.5.4.5. Reimbursement Scenario
      • 8.5.4.6. Argentina Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. MEA
    • 8.6.1. MEA Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Competitive Scenario
      • 8.6.2.4. Regulatory Framework
      • 8.6.2.5. Reimbursement Scenario
      • 8.6.2.6. South Africa Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Competitive Scenario
      • 8.6.3.4. Regulatory Framework
      • 8.6.3.5. Reimbursement Scenario
      • 8.6.3.6. Saudi Arabia Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. UAE
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Competitive Scenario
      • 8.6.4.4. Regulatory Framework
      • 8.6.4.5. Reimbursement Scenario
      • 8.6.4.6. UAE Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. Kuwait
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Competitive Scenario
      • 8.6.5.4. Regulatory Framework
      • 8.6.5.5. Reimbursement Scenario
      • 8.6.5.6. Kuwait Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant's overview
  • 9.2. Financial performance
  • 9.3. Participant categorization
    • 9.3.1. Market Leaders
    • 9.3.2. Anti-hypertensive Drugs Market Share Analysis, 2023
    • 9.3.3. Company Profiles
      • 9.3.3.1. Sanofi
      • 9.3.3.1.1. Company Overview
      • 9.3.3.1.2. Financial Performance
      • 9.3.3.1.3. Product Benchmarking
      • 9.3.3.1.4. Strategic Initiatives
      • 9.3.3.2. Boehringer Ingelheim International GmbH
      • 9.3.3.2.1. Company Overview
      • 9.3.3.2.2. Financial Performance
      • 9.3.3.2.3. Product Benchmarking
      • 9.3.3.2.4. Strategic Initiatives
      • 9.3.3.3. Novartis AG
      • 9.3.3.3.1. Company Overview
      • 9.3.3.3.2. Financial Performance
      • 9.3.3.3.3. Product Benchmarking
      • 9.3.3.3.4. Strategic Initiatives
      • 9.3.3.4. Johnson & Johnson Services, Inc.
      • 9.3.3.4.1. Company Overview
      • 9.3.3.4.2. Financial Performance
      • 9.3.3.4.3. Product Benchmarking
      • 9.3.3.4.4. Strategic Initiatives
      • 9.3.3.5. DAIICHI SANKYO COMPANY, LIMITED.
      • 9.3.3.5.1. Company Overview
      • 9.3.3.5.2. Financial Performance
      • 9.3.3.5.3. Product Benchmarking
      • 9.3.3.5.4. Strategic Initiatives
      • 9.3.3.6. Merck & Co., Inc.
      • 9.3.3.6.1. Company Overview
      • 9.3.3.6.2. Financial Performance
      • 9.3.3.6.3. Product Benchmarking
      • 9.3.3.6.4. Strategic Initiatives
      • 9.3.3.7. AstraZeneca
      • 9.3.3.7.1. Company Overview
      • 9.3.3.7.2. Financial Performance
      • 9.3.3.7.3. Product Benchmarking
      • 9.3.3.7.4. Strategic Initiatives
      • 9.3.3.8. Pfizer Inc.
      • 9.3.3.8.1. Company Overview
      • 9.3.3.8.2. Financial Performance
      • 9.3.3.8.3. Product Benchmarking
      • 9.3.3.8.4. Strategic Initiatives
      • 9.3.3.9. Lupin
      • 9.3.3.9.1. Company Overview
      • 9.3.3.9.2. Financial Performance
      • 9.3.3.9.3. Product Benchmarking
      • 9.3.3.9.4. Strategic Initiatives
      • 9.3.3.10. Sun Pharmaceutical Industries Ltd.
      • 9.3.3.10.1. Company Overview
      • 9.3.3.10.2. Financial Performance
      • 9.3.3.10.3. Product Benchmarking
      • 9.3.3.10.4. Strategic Initiatives
    • 9.3.4. Strategy Mapping
      • 9.3.4.1. Expansion
      • 9.3.4.2. Acquisition
      • 9.3.4.3. Collaborations
      • 9.3.4.4. Disease Type/Drug Class Launch
      • 9.3.4.5. Partnerships
      • 9.3.4.6. Others

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 Global Anti-hypertensive Drugs Market, by Region, 2018 - 2030 (USD Million)
  • Table 3 Global Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 4 Global Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 5 Global Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 6 Global Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 7 North America Anti-hypertensive Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 8 North America Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 9 North America Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 10 North America Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 11 North America Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 12 U.S. Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 13 U.S. Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 14 U.S. Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 15 U.S. Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 16 Canada Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 17 Canada Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 18 Canada Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 19 Canada Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 20 Europe Anti-hypertensive Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 21 Europe Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 22 Europe Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 23 Europe Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 24 Europe Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 25 Germany Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 26 Germany Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 27 Germany Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 28 Germany Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 29 UK Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 30 UK Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 31 UK Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 32 UK Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 33 France Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 34 France Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 35 France Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 36 France Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 37 Italy Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 38 Italy Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 39 Italy Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 40 Italy Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 41 Spain Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 42 Spain Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 43 Spain Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 44 Spain Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 45 Denmark Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 46 Denmark Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 47 Denmark Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 48 Denmark Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 49 Sweden Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 50 Sweden Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 51 Sweden Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 52 Sweden Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 53 Norway Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 54 Norway Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 55 Norway Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 56 Norway Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific Anti-hypertensive Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 61 Asia Pacific Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 62 China Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 63 China Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 64 China Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 65 China Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 66 Japan Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 67 Japan Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 68 Japan Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 69 Japan Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 70 India Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 71 India Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 72 India Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 73 India Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 74 South Korea Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 75 South Korea Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 76 South Korea Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 77 South Korea Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 78 Australia Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 79 Australia Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 80 Australia Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 81 Australia Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 82 Thailand Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 83 Thailand Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 84 Thailand Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 85 Thailand Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 86 Latin America Anti-hypertensive Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 87 Latin America Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 88 Latin America Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 89 Latin America Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 90 Latin America Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 91 Brazil Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 92 Brazil Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 93 Brazil Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 94 Brazil Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 95 Mexico Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 96 Mexico Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 97 Mexico Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 98 Mexico Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 99 Argentina Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 100 Argentina Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 101 Argentina Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 102 Argentina Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 103 Middle East & Africa Anti-hypertensive Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 104 Middle East & Africa Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 105 Middle East & Africa Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 106 Middle East & Africa Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 107 Middle East & Africa Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 108 South Africa Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 109 South Africa Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 110 South Africa Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 111 South Africa Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 112 Saudi Arabia Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 115 Saudi Arabia Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 116 UAE Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 117 UAE Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 118 UAE Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 119 UAE Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 120 Kuwait Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 121 Kuwait Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 122 Kuwait Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 123 Kuwait Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million) 

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Anti-hypertensive Drugs Market Segmentation
  • Fig. 8 Market Snapshot, 2023
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 PESTEL Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Global Anti-hypertensive Drugs Market: Drug Class Movement Analysis
  • Fig. 15 Global Anti-hypertensive Drugs Market, by Diuretics, 2018 - 2030 (USD Million)
  • Fig. 16 Global Anti-hypertensive Drugs Market, by ACE Inhibitors, 2018 - 2030 (USD Million)
  • Fig. 17 Global Anti-hypertensive Drugs Market, by Calcium Channel Blockers, 2018 - 2030 (USD Million)
  • Fig. 18 Global Anti-hypertensive Drugs Market, by Beta-adrenergic Blockers, 2018 - 2030 (USD Million)
  • Fig. 19 Global Anti-hypertensive Drugs Market, by Vasodilators, 2018 - 2030 (USD Million)
  • Fig. 20 Global Anti-hypertensive Drugs Market, by Others, 2018 - 2030 (USD Million)
  • Fig. 21 Global Anti-hypertensive Drugs Market: Type Movement Analysis
  • Fig. 22 Global Anti-hypertensive Drugs Market, by Primary Hypertension, 2018 - 2030 (USD Million)
  • Fig. 23 Global Anti-hypertensive Drugs Market, by Secondary Hypertension, 2018 - 2030 (USD Million)
  • Fig. 24 Global Anti-hypertensive Drugs Market: Route of Administration Movement Analysis
  • Fig. 25 Global Anti-hypertensive Drugs Market, by Oral, 2018 - 2030 (USD Million)
  • Fig. 26 Global Anti-hypertensive Drugs Market, by Injectables, 2018 - 2030 (USD Million)
  • Fig. 27 Global Anti-hypertensive Drugs Market, by Others, 2018 - 2030 (USD Million)
  • Fig. 28 Global Anti-hypertensive Drugs Market: Distribution Channel Movement Analysis
  • Fig. 29 Global Anti-hypertensive Drugs Market, by Retail Pharmacy, 2018 - 2030 (USD Million)
  • Fig. 30 Global Anti-hypertensive Drugs Market, by Hospital Pharmacy, 2018 - 2030 (USD Million)
  • Fig. 31 Global Anti-hypertensive Drugs Market, by Online Pharmacy, 2018 - 2030 (USD Million)
  • Fig. 32 Regional Marketplace: Key Takeaways
  • Fig. 33 Regional Outlook, 2023 & 2030
  • Fig. 34 Global Anti-hypertensive Drugs Market: Region Movement Analysis
  • Fig. 35 North America Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 37 Canada Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 38 Europe Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 39 Germany Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 40 UK Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 41 France Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 42 Italy Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 43 Spain Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 44 Denmark Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 45 Sweden Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 46 Norway Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 47 Asia Pacific Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 48 Japan Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 49 China Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 50 India Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 51 Australia Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 52 South Korea Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 53 Thailand Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 54 Latin America Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 55 Brazil Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 56 Mexico Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 57 Argentina Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 58 Middle East and Africa Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 59 South Africa Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 60 Saudi Arabia Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 61 UAE Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 62 Kuwait Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)